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Abstract
Background: Thymosin α1 (Tα1) as immunomodulatory treatment is supposed to be beneficial for the sepsis
patients by regulating T cell subsets and inflammatory mediators. However, limited by the small sample size and
the poor study design, the persuasive power of the single clinical studies is weak. This meta-analysis aimed to
investigate the impact of Tα1 on the sepsis patients.
Methods: We searched for the Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, CBM, VIP, CNKI,
WANFANG, Igaku Chuo Zasshi (ICHUSHI) and Korean literature databases reporting the effects of Tα1 on outcomes
in sepsis patients.
Results: Among 444 related articles, 19 randomized controlled trials (RCTs) met our inclusion criteria. Mortality
events were reported in 10 RCTs included 530 patients, and the meta-analysis showed significant decrease in Tα1
group compared with control group (RR 0.59, 95 % CI 0.45 to 0.77, p = 0.0001). The subgroup analysis showed no
difference between the two dosages (RR 0.59, 95 % CI 0.43 to 0.81; RR 0.59, 95 % CI 0.35 to 0.98, respectively). In 9
RCTs, with a total of 489 patients, Tα1 administered once per day decrease APACHE II score significantly (SMD −0.
80, 95 % CI −1.14 to −0.47, p < 0.0001) while Tα1 twice per day showed no effect (SMD 0.30, 95 % CI-0.10 to 0.70,
p = 0.14). However, the length of ICU stay, the incidence of multiple organ failure (MOF) and duration of mechanical
ventilation were not significantly affected by Tα1 treatment (SMD −0.52, 95 % CI −1.06 to 0.11, p = 0.06; SMD −0.49,
95 % CI −1.09 to 0.11, p = 0.11; SMD −0.37, 95 % CI −0.90 to 0.17, p = 0.17, respectively). As to the immunological
indicators, the level of HLA-DR were increased by Tα1 (SMD 1.23, 95 % CI 0.28 to 2.18, p = 0.01) according to the
pooled analysis of 8 studies involving 721 patients. Lymphocyte subsets CD3, CD4 and cytokines IL-6, IL-10 and
TNF-α were also beneficially affected by Tα1 treatment.
Conclusions: Tα1 may be beneficial to sepsis patients in reducing mortality and modulating inflammation
reactions. However, the quality of evidence supporting the effectiveness is low considering the small sample sizes
and inadequate adherence to standardized reporting guidelines for RCTs among the included studies.
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Background
Sepsis is a major cause of morbidity and mortality in
developed countries [1]. The mechanism of the sepsis
syndrome is not completely understood though we do
know it includes a systematic immune system response
in multiple and complex pathways which is named SIRS
(Systemic Inflammatory Reaction Syndrome) [2, 3]. Sep-
sis begins with epitope shifting from antigen presenting
cells into neutrophils, macrophages and T helper lym-
phocytes (Th), followed by cell transcription factor NF-k
B activating, entering nucleus and forming a complex
with DNA. Subsequently, apoptosis is induced and Th
lymphocytes is activated into Thl cells, which release a
large amount of proinflammatory cytokines and chemo-
kines, such as TNF-α, IL-6, IL-1β, IFN-γ and monocyte
chemoattractant protein (MCP-1), then complement and
coagulation system were activated, and systematic in-
flammation was developed, leading to high fever, shock,
coagulation dysfunction and multiple organ failure, and
even death [4–6].
Thymosin α1 (Tα1) is an acidic polypeptide consisting of
28 amino acids extracted and purified from the thymosin
fraction 5. Pharmacological studies showed that Tα1 stimu-
lates endogenous IFN-γ secretion, and enhances T cells and
the whole immune system [7–12]. Pharmacokinetic studies
in healthy volunteers showed good absorption after sub-
cutaneous injection with a peak serum level at between 1
and 2 h and a half-life of less than three hours [13]. Tα1 is
approved mainly in countries of Asia and South America,
for the treatment of chronic hepatitis B and C as a vaccine
enhancer [14]. Although some clinical trials demonstrated
that Tα1 is beneficial for the treatment of sepsis by regulat-
ing T cell subsets and inflammatory mediators [15–17], the
results are less persuasive due to the small sample size and
the poor study design. As the influence of Tα1 on progno-
sis of patients with sepsis remains inconclusive, this system-
atic review aims to quantitatively evaluate the efficacy and
safety of Tα1 in the treatment of sepsis.
Methods
Inclusion criteria
Studies are included if the following criteria are met: 1)
Randomized controlled trials (RCTs); 2) Evaluating adult
sepsis patients. We defined sepsis according to inter-
nationally accepted diagnostic criteria developed on 2001
SCCM/ESICM/ACCP/ATS/SIS international sepsis defini-
tions conference [18]. 3) Comparing Tα1 as add on ther-
apy with no treatment or placebo on the basis of standard
or conventional treatment of sepsis in both groups. Stand-
ard or conventional treatment is defined as regular treat-
ment for sepsis including adequate empiric antibiotic
therapy, ventilation regimen, blood glucose control, resus-
citation and hemodynamic support, organ support, sed-
ation or analgesia as needed and adequate nutrition.
Outcome measures
The primary outcomes are death from any cause assessed
28, 60 and 90 days after the initiation of treatment assign-
ment, the length of ventilation and the length of ICU stay-
ing. The secondary outcomes included dynamic changes
of Sequential Organ Failure Assessment (SOFA), multiple
organ dysfunction syndrome (MODS), Acute Physiology
and Chronic Health Evaluation II (APACHE II), T lympho-
cyte subsets, CD4+/CD8+, monocyte human leukocyte
antigen-DR (mHLA-DR) expression, and cytokines includ-
ing IL-6, IL-10 and TNF-α measured on day 0 (the day of
enrollment) and 7 in both groups. The rate of adverse drug
reactions was taken as indicator for tolerability.
Search strategy
We searched Cochrane Central Register of Controlled
Trials (CENTRAL) (The Cochrane Library, Issue 3 of
12, March 2016), MEDLINE (January 1966 to April 19,
2016), EMBASE (January 1980 to April 19, 2016) for
published studies and Clinicaltrials for registered studies
in English [19]. We searched China National Knowledge
Infrastructure (CBM), VIP Database for Chinese Tech-
nical Periodicals (VIP), Chinese National Knowledge
Infrastructure (CNKI) and Wanfang Data in Chinese, all
from inception to April 19, 2016. We searched Igaku
Chuo Zasshi (ICHUSHI) for Japanese literature, and
Korean literature up to February 12, 2015 [20]. We
checked the bibliographies in reports of the randomized
trials, review articles, and meta-analyses to identify other
potentially eligible studies. We used a combination of
keywords related to the names of thymosin α1 (Tα1 or
Thymosin-alpha (1) or Thymalfasin or Thymalfasine or
Thymalsasinum or Timalfasina or Zadaxin) and the type
of sepsis-associated disease (“severe infection” or “sepsis”
or “septic shock”).
Study selection
Two review authors (FL and HMW) checked titles and
abstracts identified from the register, obtained the full
text of all potentially relevant studies for independent
assessment. The authors decided independently which
trials fitted the inclusion criteria and resolved disagree-
ments by discussion or consulting the third author (XZ).
The reasons for excluding studies from the review were
documented and justified.
Data extraction and management
Two review authors (FL and HMW) performed data ex-
traction independently with a pre-tested electronic table.
Discrepancies were resolved by consensus or a third
author’s (XZ) adjudication. The following data were ab-
stracted from each study: characteristics of the studies,
characteristics of the included patients and outcomes of
the studies. The first or corresponding author of each
Liu et al. BMC Infectious Diseases  (2016) 16:488 Page 2 of 12
included study was contacted for clarifications and further
information when required.
Assessment of risk of bias in included studies
We used a domain-based evaluation as recommended by
the Cochrane Handbook 5.0.2 for Systematic Reviews of
Interventions [21]. The following domains were assessed: 1)
random sequence generation; 2) allocation concealment; 3)
blinding of participants, personnel and outcome assessors;
4) incomplete outcome data; 5) Selective reporting. 6) Bias
from other source. We graded these items as having high,
low or unclear risk. When discrepancies between review
authors existed, we reassessed the studies and reached
agreement by consensus.
Statistical analysis
We calculated the treatment effect across trials using the
Cochrane statistical package, Review Manager 5.3 (Rev-
Man). We expressed results as risk ratios (RR) with 95 %
confidence intervals (CIs) for dichotomous outcomes, such
as mortality, and mean differences (MDs) and 95 % CIs for
continuous outcomes, such as the length of ventilation, the
scores of the evaluation scales, the counts of lymphocytes
subsets and the concentration of cytokines. Heterogeneity
among studies was assessed using a Chi2 test of heterogen-
eity (P value < 0.1) and the I2 statistic [22].
Trials comparing similar regimens were pooled using
fixed effect model, unless significant heterogeneity was ob-
served when useing random-effects model. If the mean and
SD of the continuous outcomes were not reported in the
studies, we assigned the median as the mean if sample size
was greater than 25 and estimated the SD from the range
(that is, SD range 0.95/4 or interquartile range/1.35) as sug-
gested by Hozo et al. [23]. If sample size was less than 25
we used formulas suggested by Hozo et al. to calculate the
mean [23]. If we could not calculate the mean or SD from
the available data, we excluded the study from the analysis.
Sensitivity analysis
We undertook sensitivity analyses taking into account the
quality of the studies. To evaluate a single study’s effect on
the pooled data, sensitivity analysis was carried out by
excluding each study. Publication bias was evaluated using
Funnel plots and Fail-Safe Number (Nfs) [24].
Subgroup analysis and investigation of heterogeneity
We explored sources of heterogeneity with a priori sub-
group hypotheses: dosage regimen of Tα1. Patients received
subcutaneous injections of 1.6 mg Tα1 (ZADAXIN™, Sci-
Clone Pharmaceuticals, Foster City, CA, USA) twice per
day for 5 consecutive days, then once per day for 2 con-
secutive days.
Results
Characteristics of included studies
From electronic searches and hand searches,we retrieved
444 relevant publications. A total of 248 articles were
obtained from initial screening, and 19 RCTs involving
1354 adult patients were included in the meta-analysis.
A detailed flowchart of the search and selection results
is shown in Fig. 1. All the included studies [25–43] were
conducted in China. The key characteristics of included
trials were summarized in Table 1. The prior or preexist-
ing conditions were addressed as burn, hospital-acquired
pulmonary infection and abdominal infection respect-
ively in three studies [28, 29, 37], however, the patients
included in these studies comply the diagnosis criteria of
sepsis. Of the 19 RCTs, 14 included studies [25–36, 42,
43] used Tα1 1.6 mg per day and 5 studies [37–41] used
1.6 mg, twice per day, both administered subcutaneously.
Risk of bias in included studies
The quality of the included studies was assessed using the
criteria defined in the Cochrane Handbook 5.0.2 [21]. The
assessments and grades given are shown in Table 2. Only
2 out of 19 trials were considered as high quality.
The impact on mortality
None of the included studies reported 60 and 90-day
mortality.
Fig. 1 Flow diagram for study selection. A detailed flowchart of the
search and selection results is shown in this figure
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Table 1 Characteristics of included studies. SSC therapy: Surviving Sepisis Campaign therapy









Sepsis patients in ICU,
age over 18 years
40, 20/20 SSC therapy + Tα1, 1.6 mg,SC,QD SSC therapy + NS Levels of CD3,CD4,CD8, CD4/CD8, NK,CRP, APACHE II
Cheng AB 2010
[26]
Sepsis patients in ICU,
age under 70 years and
HLA-DR < 30 %
60,30/30 Conventional treatment + Tα1,
1.6 mg, SC, QD
Conventional
treatment + NS
Levels of CD4,CD8 and HLA-DR
Gui CM 2012
[27]
Sepsis patients in ICU,
age between 18 and
80 years
42,22/20 SSC therapy + Tα1, 1.6 mg,SC,QD SSC therapy Levels of CD4, CD4/CD8, igg, iga, igm, PCT, IL-6,





45,24/21 Conventional treatment + Tα1,
1.6 mg, SC, QD
Conventional
treatment + NS
Levels of TNF-α, IL-6, IL-10, CD3,CD4,CD8, CD4/CD8,
NK and 28-day mortality
Gong ZH 2011
[29]
Burn sepsis patients 56,28/28 Conventional treatment + Tα1,
1.6 mg, SC, QD
Conventional
treatment
Levels of TNF-α, and WBC
Chen J 2007
[38]
Septic shock, APACHE II
scores between 15 and 20
42,21/21 SSC therapy + Tα1, 1.6 mg,SC, BID SSC therapy Levels of T-lymphocyte subtype, natural killer cell




Sepsis patients or septic
shock
120,60/60 Conventional treatment + Tα1,
1.6 mg, SC, QD
Conventional
treatment
Levels of CD4, CD8, CD4/CD8, APACHE II and 28-day
mortality
Lei S 2005 [37] Severe hospital acquired
pneumonia patients in ICU,
HLA-DR <30 %,
38,21/17 Conventional treatment + Tα1,
1.6 mg, SC, BID
Conventional
treatment
Levels of CD4, CD8, CD4/CD8, NK, HLA-DR and 28-day
mortality
Li YN 2009 [31] Age over 18 years, suffering
from severe sepsis with
Marshall score over 5
47, 23/24 SSC therapy + Tα1, 1.6 mg,SC, QD SSC therapy Levels of HLA-DR, CD3, CD4, CD8, length of ICU stay,
APACHE II, 28-day mortality and mechanical ventilation time
Wu JN 2004
[32]
Sepsis patients in ICU,
HLA-DR <30 %
44,22/22 Conventional treatment + Tα1,
1.6 mg, SC, QD
Conventional
treatment + NS
Levels of HLA-DR, CRP, APACHE II; and MOF
Wu JF 2013
[39]
Patients in ICU with severe
sepsis
361,181/180 Conventional treatment + Tα1,
1.6 mg, SC, twice per day for 5
consecutive days, then once per
day for 2 consecutive days
Conventional
treatment + NS
Levels of HLA-DR, CD4/CD8, WBC, duration of ICU stay,
mechanical ventilation time, APACHE II and 28-day mortality
Wu JF 2014
[40]
Sepsis patients, age over
18 years
54,26/28 Conventional treatment + Tα1,
1.6 mg, SC, twice per day for
5 consecutive days, then once per










Level of IL-6 and APACHE II
Zhang Z 2006
[33]




Levels of CRP, CD3, CD4, CD8, CD4/CD8, NK, and APACHE II
Zhou LX 2009
[35]
Severe sepsis aged > 18,
Marshall score > 5
47, 23/24 Tα1 plus SSC therapy SSC therapy IL-6, IL-10, TNF-α, HLA-DR, T lymphocytes, 28-day mortality
Zhao MY 2007
[34]
Sepsis patients in ICU,
HLA-DR <30 %, age <70

















Table 1 Characteristics of included studies. SSC therapy: Surviving Sepisis Campaign therapy (Continued)
Zhou Q 2011
[36]
Severe sepsis, age >
18 years
82,42/40 SSC therapy + Tα1, 1.6 mg,SC,QD SSC therapy Levels of HLA-DR, CD3, CD4, CD8, CD4/CD8
Zhu 2015 [43] Severe sepsis, age >
18 years
60,30/30 Conventional treatment + Tα1,
1.6 mg, SC, QD
Conventional
treatment + NS
Levels of, CD3, CD4, CD8, CD4/CD8,
duration of ICU stay and APACHE II
Lu 2015 [42] Patients with siai, age >
18 years
76,38/38 Conventional treatment + Tα1,
1.6 mg, SC, twice a week
Conventional
treatment + NS













Primary analysis of 28-day mortality
A total of 10 studies reported mortality within 28 days,
including a total of 530 patients and 158 events (Fig. 2).
No significant heterogeneity was found across the 10
studies (Chi 3.81, I2 0 %, p = 0.92). Furthermore, we de-
tected no evidence of publication bias after a funnel plot
analysis (Fig. 3), and Nfs0.05 = 36.04. The RR showed a
significant decrease of mortality in Tα1 group com-
pared with control group (RR 0.59, 95 % CI 0.45 to
0.77, p = 0.0001) (Fig. 2).
Subgroup analysis of 28-day mortality
To explore the relationship between different dose of
Tα1 and 28-day mortality, we conducted the subgroup
analyses. The intervention of Tα1 administered once per
day was adopted in 7 trials involving 396 patients and
the intervention of Tα1 administered twice per day was
adopted in three trials involving 134 patients. The sub-
group analysis showed both the two dosage regimens
significantly decreased mortality of sepsis patients (Tα1
once per day: RR 0.59, 95 % CI 0.43 to 0.81; Tα1 twice
per day: RR 0.59, 95 % CI 0.35 to 0.98) (Fig. 2).
The impact on APACHE II
Primary analysis
Nine studies involving 489 patients reported APACHE II
score. There was a significant difference in APACHE II
score reduction between Tα1 and control group (SMD
−0.55, 95 % CI −0.97 to −0.13, p = 0.01), which meant
that Tα1 decreased APACHE II in a greater degree than
control group. Since the heterogeneity was high (Chi
39.82, I2 80 %) (Fig. 4) among different studies, we con-
ducted subgroup analysis.
Subgroup analysis
The intervention of Tα1 administered once per day was
adopted in 7 trials involving 391 patients and the inter-
vention of Tα1 twice per day was adopted in two trials
involving 98 patients (Fig. 4).
SMD for Tα1 once per day group was −0.80 (95 % CI
−1.14 to −0.47, p < 0.00001) with a moderate heterogeneity
(Chi 14.26, I2 58 %, p = 0.03).
However, the effect of Tα1 twice per day on APACHE II
was not statistically significant (SMD 0.30, 95 % CI-0.10 to
0.70, p = 0.14). No significant heterogeneity was found
across the 2 studies (Chi 0.34, I2 0 %, p = 0.56).
The impact on MOF
Only one study involving 44 patients reported the inci-
dence of multiple organ failure (MOF). As shown in
Table 3, there was no significant difference on MOF
between Tα1 and control group. (SMD −0.49, 95 %
CI −1.09 to 0.11, p = 0.11).























Chen XL 2009 Unclear Unclear Unclear Unclear Unclear Low risk Low risk Low risk
Cheng AB 2010 Unclear Unclear Unclear Unclear Unclear Unclear Low risk Low risk
Gui CM 2012 High risk High risk Unclear Unclear Unclear Low risk Low risk Low risk
Hu XY 2007 Unclear Unclear Unclear Unclear Unclear Unclear Low risk Low risk
Gong ZH 2011 Low risk Unclear Unclear Unclear Unclear Low risk Low risk Low risk
Chen J 2007 Unclear Unclear Unclear Unclear Unclear Low risk Low risk Low risk
Fan JB 2014 Unclear Unclear Unclear Unclear Unclear Unclear Low risk Low risk
Lei S 2005 Unclear Unclear Unclear Unclear Unclear Unclear Low risk Low risk
Li YN 2009 Unclear Unclear Unclear Unclear Unclear Low risk Low risk Low risk
Wu JN 2004 Low risk Low risk Unclear Unclear Unclear Unclear Low risk Low risk
Wu JF 2013 Low risk Low risk Low risk Low risk Low risk Low risk Low risk Low risk
Wu JF 2014 Low risk Low risk Low risk Low risk Low risk Low risk Low risk Low risk
Zhang BJ 2014 Unclear Unclear Unclear Unclear Unclear Low risk Low risk Low risk
Zhang Z 2006 Unclear Unclear Unclear Unclear Unclear Unclear Low risk Low risk
Zhou LX 2009 Unclear Unclear Unclear Unclear Unclear Low risk Low risk Low risk
Zhao MY 2007 Low risk Low risk Unclear Unclear Unclear Low risk Low risk Low risk
Zhou Q 2011 Low risk Low risk Unclear Unclear Unclear Low risk Low risk Low risk
Zhu SJ 2015 Unclear Unclear Unclear Unclear Unclear Low risk Low risk Low risk
Lu FP 2015 Unclear Unclear Unclear Unclear Unclear Low risk Low risk Low risk
Liu et al. BMC Infectious Diseases  (2016) 16:488 Page 6 of 12
The impact on mechanical ventilation days
Six studies reported duration of mechanical ventilation,
and a total of 570 patients were included. As shown in
Table 3, there was no significant difference on the mech-
anical ventilation days between Tα1 and control group
(SMD −0.37, 95 % CI −0.90 to 0.17, p = 0.17). However,
heterogeneity was high (Chi 32.24, I2 84 %, p < 0.001).
The impact on length of ICU stay
Six studies involving 591 patients reported the length of
ICU stay. As shown in Table 3, there was no significant
difference on the length of ICU stay between Tα1 and
control group. SMD was −0.52 (95 % CI −1.06 to
0.01, p = 0.06) with high heterogeneity (Chi 34.92, I2
86 %, p <0.0001).
The impact on HLA-DR levels
Eight studies including 721 patients reported the level
of HLA-DR. There was a significant difference in HLA-
DR between Tα1 and control group. SMD was 1.23 (95
% CI 0.28 to 2.18, p = 0.01), with a high heterogeneity
(Chi 179.65, I2 96 %) (Fig. 4). To explore the high
heterogeneity among different studies, we conducted
subgroup analysis.
Fig. 3 Funnel plot of the published studies in relation to the 28-day mortality meta-analysis. Ten studies were included. No evidence of a publication
bias in a funnel plot analysis
Fig. 2 The effect of thymosin α1 on 28-day mortality. A total of 10 studies reported mortality within 28 days, and it included a total of 530 patients
and 158 events
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Subgroup analysis
The group of Tα1 administered once per day included
six trials with 322 patients and the group of Tα1 admin-
istered twice per day included two trials with 399 pa-
tients. The subgroup analysis showed a significant effect
of Tα1 once per day on HLA-DR (SMD 0.86, 95 % CI
0.50 to 1.23, p < 0.001) with a moderate heterogeneity
(Chi 12.24, I2 59 %, p = 0.03). However, the effect of Tα1
twice per day on HLA-DR was not statistically signifi-
cant (SMD 2.26, 95 % CI-0.12 to 4.64, p = 0.06) with a
significant heterogeneity (Chi 39.47, I2 97 %, p < 0.001)
(Fig. 5).
The impact on T lymphocyte subsets
Tα1 showed significantly better effect on CD3+, CD4+
and CD4+/CD8+ than control, but didn’t show differ-
ence on CD8+. The pooled results were showed in
Table 4. However, there was a high heterogeneity across
these studies.
The impact on cytokines
IL-6 levels Four studies involving 189 patients reported
the level of IL-6. There was no significant difference
on the level of IL-6 between Tα1 and control group
(SMD −0.32, 95 % CI −1.24 to 0.60, p = 0.49), and the
heterogeneity across the four studies was high (Chi 28,
I2 89 %, p < 0.0001) (Table 5).
IL-10 levels Three studies involving 129 patients re-
ported the level of IL-10. There was a significant differ-
ence on the level of IL-10 between Tα1 and control
group (SMD 1.06, 95 % CI 0.64 to 1.49, p < 0.00001). No
significant heterogeneity was found across the 3 studies
(Chi 2.63, I2 24 %, p = 0.27) (Table 5).
TNF-α levels Four studies involving 190 patients re-
ported the level of TNF-α. There was a significant differ-
ence on the level of TNF-α between Tα1 and control
group (SMD −0.47, 95 % CI −0.76 to −0.18, p = 0.002).
No significant heterogeneity was found across the 5
studies (Chi 2.55, I2 0 %, p = 0.47) (Table 5).
Safety of Tα1 The included RCTs reported neither Tα1
related severe adverse event nor treatment discontinu-
ation due to intolerance or adverse events of Tα1.
Discussion
In this systematic review of RCTs including1354 patients
with sepsis, we found benefits of Tα1 on both survival
and other clinical indicators. We also explored the effi-
cacy of Tα1 on immune parameters.
Overall completeness and applicability of evidence
The trials were identified following a systematic search
of the literature in multi-language databases. Besides
English and Chinese databases, we additionally searched
Table 3 The influence on MOF, length of ICU stay and mechanical ventilation days
Included studies Cases Chi I2 % SMD 95 % CI P
MOF 1 [32] 44 – – −0.49 −1.09,0.11 0.11
Length of ICU stay 6 [31, 33, 35, 37, 39, 43] 591 34.92 86 % −0.52 −1.06,0.01 0.06
Mechanical ventilation days 6 [31, 33, 35, 37–39] 570 32.24 84 % −0.37 −0.90, 0.17 0.17
Fig. 4 The effect of thymosin α1 on APACHE II. Nine studies reported APACHE II score, and 489 patients were included. There was a significant
difference in APACHE II score between thymosin α1 and control group
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Japanese and Korean database to enhance our systematic
review’s ability of reflecting international practice. Study
inclusion criteria were tightly defined and the meta-
analysis was rigorously conducted according to a prede-
fined analysis plan addressing specific hypotheses.
We didn’t set limitations on the primary etiologies of
sepsis, however, all trials included critically ill patients
where a common systemic inflammatory pathway was
activated. Therefore, we think that there is a good bio-
logic reason to perform a broad meta-analysis, which
also considerably increases the generalizability and use-
fulness of the review.
The data of lymphocyte subsets and cytokines were col-
lected at the 7th day of treatment course of Tα1 in most of
the included studies and had the same tendency of favoring
Tα1 group as 28 days’ mortality, which indicates that those
data can be served as prognosis indicator for sepsis. Our
systematic review is consistent with recent studies indicated
that the relationship of cytokines and mortality of sepsis
[44–46].
In subgroup analysis, both Tα1 1.6 mg once daily and
1.6 mg twice daily decreases mortality, APPACHE II score,
ventilation days and ICU days, and they also showed posi-
tive effect on lymphocyte subsets and cytokines. Though
we didn’t carried out comparisons between the two regi-
mens, we recommend Tα1 1.6 mg once daily to be used
for cost-effectiveness considerations.
The role of Tα1 in immune modulatory therapy of sepsis
It was indicated in a variety of studies that Tα1 modu-
lated immune functions through multiple pathways;
however, its mechanism was not fully established [47].
Recent studies suggested that Tα1 combines to toll like
receptors (TLRs) located in the surface of dendritic cells
(DC), and thus activates them into effector cells with the
function of stimulating or inhibiting T cells [48]. As
highly specialized type of antigen-presenting cell (APC),
DC activate CD3+ (total T cells), CD4+ (helper T cells),
and CD8+ (cytotoxic T cells), which is considered as im-
portant pathway for Tα1 to reverse immune suppression
in sepsis. Moreover, plasmacytoid dendritic cells pro-
mote the function of regulatory T Cells, which increase
the production of anti-inflammatory factors, such as IL-10
and TGF-β, and reduce the pro-inflammatory cytokines,
such as IL-2, IL-6 and TNF-α, so that to combat against
the pro-inflammatory cytokines storm in early period of
sepsis and then modulate the over-stimulating of nonspe-
cific immunity in the deferment period later on [49].
HLA-DR is expressed in the surface of B-lymphocytes,
macrophages, activated T lymphocytes and other immune
cells, and the decline of HLA-DR expression is proposed
as a reflection of immunosuppression in critically ill
patients [50].
Our study shows Tα1 increased CD3+, CD4+, and
CD4+/CD8+, as well as the level of HLA-DR, which
Table 4 The influence on lymphocyte subsets
Lymphocyte subsets Included studies Cases Chi I2 % SMD 95 % CI P
CD3 9 [25, 28, 31, 33, 35, 36, 38, 42, 43] 521 56.12 86 % 0.84 0.35,1.33 0.0008
CD4 14 [25–28, 30, 31, 33–38, 42, 43] 779 51.01 75 % 0.80 0.50,1.10 <0.0001
CD8 12 [25, 26, 28, 30, 31, 33–37, 42, 43] 695 62.64 82 % −0.27 −0.64,0.10 0.16
CD4/ CD8 13 [25, 27, 28, 30, 31, 33, 35–39, 42, 43] 1038 102.37 88 % 0.62 0.22,1.02 <0.0001
Fig. 5 The effect of thymosin α1 on HLA-DR levels. Eight studies including 721 patients reported the level of HLA-DR. There was a significant
difference in HLA-DR between thymosin α1 and control group
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comply with the results of basic research. However, Tα1
did not demonstrate a significant impact on CD8+. As to
the influence on cytokines, our study showed that Tα1
decreased the level of TNF-α and increased IL-10, but
had no significant effect on IL-6. Besides that, it was
suggested by both basic research and clinical trials that
multiple kinds of other cytokines experience significant
changes with the progress of sepsis, including IL-2, IL-3,
IL-4 and IFN-γ etc. However, those cytokines were
barely evaluated in the included studies. Therefore, more
studies, both fundamental and clinical are needed for
further understanding the immune-modulatory effect of
Tα1 on different immune cells and cytokines with the
progress of sepsis.
Safety of Tα1
According to package insert of Tα1, the rate of adverse
reactions of Tα1 is less than 1 % across all its indica-
tions. The reported ADRs include pain, redness, and
transient muscle atrophy in injection site, multiple joint
pains with swelling, and rash. Both Li [51] and our sys-
tematic reviews included adverse reactions to evaluate
Tα1’s tolerability, and no severe ADRs were recorded in
the included clinical trials.
Comparisons with published review
Three similar systematic reviews had been published re-
cently [51–53]. All of them took Tα1-based immune mod-
ulatory therapy as intervention, which means they included
not only Tα1, but also concomitantly used ulinastatin. Han
[52] evaluated combination of ulinastatin and Tα1, but not
Tα1 monotherapy. For Tα1 monotherapy groups, the
recently published reviews included fewer studies than
ours, which may because they searched less Chinese litera-
ture database. For outcomes, all the systematic reviews took
mortality as primary outcomes, while durations of mechan-
ical ventilation and ICU stay were evaluated in both Han
and Feng’s review, and APACHE II in Feng’s review. Com-
pared to that, our study also included MOF score, hoping
to provide some hint on efficacy of Tα1 in organ dysfunc-
tion in sepsis though we didn’t come to a definite conclu-
sion because of the limited number of included study.
Furthermore, the studies by Li and Feng [51, 53] failed to
include immune indicators, while Han evaluated TNF-α
and IL-6 [52]. We considered more immune indicators
since it was implicated in previous studies shat Tα1 showed
pleiotropic effects on immune system [54]. We hope the
meta-analysis of immune parameters will be helpful to find
out the factors to predict the efficacy of Tα1 in sepsis.
Furthermore, providing communitive clinical evidence as
meta-analysis may indicate directions for subsequent fun-
damental researches on the immunomodulatory mechan-
ism of Tα1 in treating sepsis.
We didn’t include studies evaluating efficacy of con-
current use of Tα1 and ulinastatin, except for the studies
where ulinastatin were used as background therapy.
According to present study, it seems that immune-
modulatory effects between Tα1 and ulinastatin overlap
each other especially when it comes to their effects on
proinflammatory mediators. To figure out to what extent
Tα1 is responsible for the beneficial effects noted in the
clinical trials, we decided to focus on the studies evaluating
the efficacy of Tα1 monotherapy. Future studies providing
head-to-head comparison between Tα1 and ulinastatin
may be beneficial to further discover the pathway by which
immune modulators pose influence on physiopathology of
sepsis.
Limitations of the review
The meta-analysis combined data from a group of predom-
inantly underpowered single center studies. Although there
was minimal heterogeneity among trial results on mortality,
we are aware that we pooled clinical trials with high risk of
bias, thus, the validity of our meta-analysis may be criti-
cized. Another concern is that great heterogeneity existed
in the meta-analysis of lymphocyte subsets and cytokines,
which may be related to the different measure methods
across the included studies. We used standardized mean
deviation and carried out sensitivity analysis, and it was
showed that the pooled results were stable after removal
the studies with heterogeneity.
In 2015, the Society of Critical Care Medicine pro-
posed the new definition of sepsis, which demonstrated
sepsis as a life-threatening organ dysfunction (OD) due
to a dysregulated host response to infection. SOFA was
the major tool to evaluate organ dysfunction, and was
shown to be associated with prognosis of sepsis [55]. We
included SOFA in our secondary outcomes, regretfully,
none of the included studies used SOFA to evaluate effi-
cacy of Tα1.
Conclusion
In summary, Tα1 may have some benefits in reducing
28 day mortality, deceasing APPACHE II score and
Table 5 The influence on cytokines (interleukins and TNF-α)
Cytokines Included studies Cases Chi I2 % SMD 95 % CI P
IL-6 4 [27, 28, 34, 41] 189 28 89 % −0.32 −1.24,0.6 0.49
IL-10 3 [27, 28, 34] 129 2.63 24 % 1.06 0.64,1.49 <0.00001
TNF-α 4 [28, 29, 34, 35] 190 2.55 0 % −0.47 −0.76,–0.18 0.002
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modulating immune parameters in sepsis patients, how-
ever, the quality of evidence is low. More high-quality
studies are needed to confirm Tα1 efficacy in improving
clinical outcomes and provide comprehensive under-
standing of its immumodulatory role in sepsis.
Key messages
 In sepsis patients, Tα1 decreased 28 days mortality
on the basis of regular therapy.
 Both Tα1 1.6 mg once daily and 1.6 mg twice
daily had the effect to decrease mortality and
APPACHE II score.
 Tα1 increased the level of IL-10 among sepsis
patients.
 Tα1 reduced the level of TNF-α among sepsis
patients.
 Sepsis patients benefited from Tα1 as
immunomodulatory treatment.
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